07:00 , Jul 19, 2010 |  BioCentury  |  Finance

Rationalizing DeveloGen

A total of $61.1 million in venture money went into DeveloGen AG in its three financing rounds from 1998-2004, but Evotec AG (Xetra:EVT) will get the metabolic and endocrine company for no more than €14...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Ebb & Flow

Amgen...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Nomura's investments

Nomura's investments...
08:00 , Feb 25, 2008 |  BioCentury  |  Finance

Ebb & Flow

Encysive...
08:00 , Dec 10, 2007 |  BioCentury  |  Finance

Ebb & Flow

Genentech...
07:00 , Mar 12, 2007 |  BioCentury  |  Finance

Too much money

In 2002, MPM Capital closed what was the largest-ever dedicated healthcare fund. At $940 million, BioVentures III was intended to allow the firm to put its capital to work in $50-$100 million chunks as part...
01:20 , Mar 6, 2007 |  BC Extra  |  Financial News

MPM Capital closes $550 million fund

MPM Capital closed its MPM BioVentures IV at $550 million. MPM said 85% of the fund will be invested in biotech and specialty pharmaceuticals, with the remainder going to medtech, tools and diagnostics. MPM expects...
07:00 , Sep 25, 2006 |  BioCentury  |  Strategy

Midcap wake-up call

For years, it has been an open secret that many of Europe's family-owned mid-cap pharmas have been lost at sea, unable to adapt to the new world of innovative in-house R&D and aggressive in-licensing. Merck...
07:00 , Jun 19, 2006 |  BioCentury  |  Finance

Ebb & Flow

Investors gave a cool response to...
07:00 , May 8, 2006 |  BioCentury  |  Finance

U.S. investment in Europe

U.S. investment in Europe...